Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 85.25% shareholder participation, with 55,924,987 of 65,600,370 shares represented.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 85.25% shareholder participation, with 55,924,987 of 65,600,370 shares represented
- Christopher Bowden and Carolyn Ng reelected as Class II directors through 2029
- KPMG LLP appointment ratified for fiscal year ending December 31, 2026
- Auditor vote showed 55,914,602 for, 8,815 against, and 1,570 abstaining
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.